Friday the 18th of Feb 2022 is the day Vladimir Misik and a multidisciplinary team of clinical research experts worked towards for more than a year. The formal launch of the Report on Industry Clinical Trials in Poland – Possibilities to increase number and scope of trials in Poland, procured by Polish associations of innovative pharmaceutical manufacturers and of CROs, INFARMA – The Employers’ Union of Innovative Pharmaceutical Companies and POLCRO.

Biopharmaceutical industry clinical trials in Poland

Since the mid 1990s Poland, together with the rest of CEE, has grown into a powerhouse of innovative biopharmaceutical industry clinical trials (iBPCT): in 2019 it ranked 11th globally in terms of iBPCT market share, and during the 2014-2019 period posted 5th largest iBPCT market share gain globally, behind China, Spain, South Korea and Taiwan (details on ranking methodology are provided in our report)*. The socioeconomic impact of this market share for Poland is very significant: in 2019 the economic value of iBPCTs represented more than USD 1.3 billion (15% of total R&D investment in Poland), some nine thousand jobs in Poland were related to iBPCT, and more than 25,000 Polish patients gained access to cutting edge experimental therapies in 2019 alone. In 2019, Poland ranked 12th globally in terms of population-adjusted accessibility to experimental therapies, and ranked 7th in terms of industry-country reputation index (details on ranking methodology are provided in our report)*.

*Data analytics in the Report were powered by LongTaal – Clinical Trial Analytics.

Scenarios of iBPCT markets trends in Poland

This report identified the following scenarios of iBPCT markets trends in Poland:

  • Growth: market share growth of 3.5% p.a. during 2021-2030
    however, there is a reasonable probability of an alternative scenario:
  • Correction: a market share decline (approx. 25% between 2021-2030) driven by one of the largest imbalances (7th globally) between pharmaceutical market share and share of clinical trials

The delta between the Growth and the Correction scenarios would be USD 6.3 billion during the 2021-2030 period, with an annual impact of USD 1.3 billion in 2030. It is the delta which is the opportunity prize to go after by adopting bold, growth-focused measures described in the Report.

Access the full report

Special thanks

Special thanks to (shown in alphabetical order): Agnieszka Skoczylas; Anna Kacprzyk; Bartek Jarosz; Douglas Drake; Krystyna Miłowska; Le Vin Chin; Lukasz Beczkowski; Magdalena Czarnecka; Piotr Zięcik; Przemyslaw Magielski; Tomek Dabrowski; Wojciech Szczepanik and to collaborating companies: LongTaal – Clinical Trial Analytics; VIARES; Clinscience; Clinerion Ltd; Grupa NEUCA; Pratia; ZFLegal Ziecik Milowska i Partnerzy Adwokaci i Radcowie Prawni.